How safe is it, really?

Therapeutic dose is not wild infection.

For most of human history, people carried dozens — sometimes hundreds — of intestinal worms, acquired from contaminated water and soil. Those heavy infections caused real suffering: malnutrition, anaemia, stunted growth in children. That picture is not what helminthic therapy involves.

A typical starting hookworm dose is twenty-five larvae; many begin with fewer. None of the organisms used can reproduce inside the host — this is also what prevents any person-to-person spread. If needed, standard deworming medication clears them within days.

The illustration to the right holds both scales in the same frame. This distinction — between the weight of wild infection and the careful arithmetic of a therapeutic dose — is the most important thing to carry through this chapter.

Unapproved is not untested.

No health authority has approved helminthic therapy as a treatment — organisms are supplied for research purposes. This is importantly different from saying the therapy has never been studied.

Pig whipworm (TSO) passed every safety evaluation required by the U.S. FDA, the German BfArm, and the equivalent agencies of Denmark, Switzerland, Austria and the Czech Republic before any of those agencies permitted human clinical trials to proceed. Those trials added further confirmation of safety. Human hookworm (NA) has been studied in formal trials at universities in the UK and Australia — across more than five hundred participants, with no deaths observed.

The Centers for Disease Control (CDC) classifies therapeutic hookworm doses as 'light' infections — a category they explicitly determine requires no treatment.

The immunologist William Parker, who has compiled the most rigorous dataset of self-treaters, puts it plainly: remaining helminth-free is not a neutral choice. The immune system missing its co-evolved companions is itself in a pro-inflammatory state — itself a risk. The question is not 'risk versus safety' but which risk, weighed carefully.